Posted by Michael Wonder on 04 May 2020
Gilead’s investigational anti-viral remdesivir receives U.S. FDA emergency use authorisation for the treatment of COVID-19
1 May 2020 - Authorisation enables broader use of remdesivir to treat hospitalised patients with severe COVID-19 disease in the United States.
Gilead today announced that the U.S. FDA has granted emergency use authorisation (EUA) for the investigational antiviral remdesivir to treat COVID-19. The EUA will facilitate broader use of remdesivir to treat hospitalised patients with severe COVID-19 disease, enabling access to remdesivir at additional hospitals across the country.
Allocation of the currently limited available supply of remdesivir will be made based on guiding principles that aim to maximise access for appropriate patients in urgent need of treatment, with direction from and in collaboration with the government.
